Verastem Competitors

Verastem (NASDAQ:VSTM) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Risk and Volatility

Verastem has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Verastem and Amgen, as provided by MarketBeat.

Verastem currently has a consensus price target of $3.00, suggesting a potential upside of 8.70%. Amgen has a consensus price target of $259.4091, suggesting a potential upside of 4.20%. Given Verastem's stronger consensus rating and higher possible upside, equities research analysts clearly believe Verastem is more favorable than Amgen.

Insider and Institutional Ownership

42.2% of Verastem shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 2.9% of Verastem shares are held by company insiders. Comparatively, 0.4% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Verastem and Amgen's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Verastem and Amgen's gross revenue, earnings per share and valuation.

Amgen has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Summary

Amgen beats Verastem on 10 of the 14 factors compared between the two stocks.

Verastem (NASDAQ:VSTM) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Volatility and Risk

Verastem has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Earnings & Valuation

This table compares Verastem and Gilead Sciences' revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

42.2% of Verastem shares are held by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are held by institutional investors. 2.9% of Verastem shares are held by insiders. Comparatively, 0.1% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Verastem and Gilead Sciences, as reported by MarketBeat.

Verastem presently has a consensus target price of $3.00, suggesting a potential upside of 8.70%. Gilead Sciences has a consensus target price of $97.2308, suggesting a potential upside of 49.33%. Given Gilead Sciences' higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Verastem.

Profitability

This table compares Verastem and Gilead Sciences' net margins, return on equity and return on assets.

Summary

Gilead Sciences beats Verastem on 10 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Verastem (NASDAQ:VSTM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Profitability

This table compares Vertex Pharmaceuticals and Verastem's net margins, return on equity and return on assets.

Volatility and Risk

Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Verastem has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Vertex Pharmaceuticals and Verastem, as reported by MarketBeat.

Vertex Pharmaceuticals presently has a consensus price target of $293.1250, suggesting a potential upside of 37.39%. Verastem has a consensus price target of $3.00, suggesting a potential upside of 8.70%. Given Vertex Pharmaceuticals' higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Verastem.

Insider & Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.2% of Verastem shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 2.9% of Verastem shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Vertex Pharmaceuticals and Verastem's top-line revenue, earnings per share and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Verastem on 12 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Verastem (NASDAQ:VSTM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Regeneron Pharmaceuticals and Verastem, as reported by MarketBeat.com.

Regeneron Pharmaceuticals currently has a consensus target price of $637.2083, indicating a potential upside of 34.10%. Verastem has a consensus target price of $3.00, indicating a potential upside of 8.70%. Given Regeneron Pharmaceuticals' higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Verastem.

Profitability

This table compares Regeneron Pharmaceuticals and Verastem's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Regeneron Pharmaceuticals and Verastem's top-line revenue, earnings per share (EPS) and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Verastem has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Insider & Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 42.2% of Verastem shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 2.9% of Verastem shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Regeneron Pharmaceuticals beats Verastem on 12 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Verastem (NASDAQ:VSTM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.

Profitability

This table compares Biogen and Verastem's net margins, return on equity and return on assets.

Institutional and Insider Ownership

83.5% of Biogen shares are held by institutional investors. Comparatively, 42.2% of Verastem shares are held by institutional investors. 0.5% of Biogen shares are held by company insiders. Comparatively, 2.9% of Verastem shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Biogen has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Verastem has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Earnings and Valuation

This table compares Biogen and Verastem's top-line revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Biogen and Verastem, as provided by MarketBeat.

Biogen presently has a consensus price target of $303.5517, suggesting a potential upside of 13.19%. Verastem has a consensus price target of $3.00, suggesting a potential upside of 8.70%. Given Biogen's higher probable upside, equities analysts plainly believe Biogen is more favorable than Verastem.

Summary

Biogen beats Verastem on 10 of the 14 factors compared between the two stocks.

Verastem (NASDAQ:VSTM) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.

Institutional & Insider Ownership

42.2% of Verastem shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 2.9% of Verastem shares are owned by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Verastem has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Valuation and Earnings

This table compares Verastem and Alexion Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Verastem and Alexion Pharmaceuticals, as provided by MarketBeat.com.

Verastem presently has a consensus price target of $3.00, indicating a potential upside of 8.70%. Alexion Pharmaceuticals has a consensus price target of $153.8636, indicating a potential downside of 0.74%. Given Verastem's stronger consensus rating and higher probable upside, analysts plainly believe Verastem is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares Verastem and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Alexion Pharmaceuticals beats Verastem on 12 of the 15 factors compared between the two stocks.